ArticleClinical & developmental immunology2010
Tumor antigen cross-presentation and the dendritic cell: where it all begins?
Article in Clinical & developmental immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy.Lasers in surgery and medicine · 2018Trial
- Causal Exposures of Immune Cells in Neuromyelitis Optica Spectrum Disorders: A Mendelian Randomization Study and Flow Cytometry Analysis.Brain and behavior · 2026Article
- Innovative gene engineering and drug delivery systems for dendritic cells in cancer immunotherapy.Journal of biomedical science · 2025Review
- What do cancer-specific T cells 'see'?Discovery immunology · 2023Review
- Relationship between the tumor microenvironment and the efficacy of the combination of radiotherapy and immunotherapy.International review of cell and molecular biology · 2023Article
- How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies.Frontiers in pharmacology · 2022Review
- IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer.Molecular cancer therapeutics · 2021Article
- Article
- HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy.International journal of molecular sciences · 2020Observational
- Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.Journal for immunotherapy of cancer · 2020Article
- NaCl Nanoparticles as a Cancer Therapeutic.Advanced materials (Deerfield Beach, Fla.) · 2019Article
- Kinetics of immune cell responses in the multiple low-dose streptozotocin mouse model of type 1 diabetes.FASEB bioAdvances · 2019Article
- Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab.Molecular and clinical oncology · 2019Article
- The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy.Frontiers in medicine · 2018Article
- Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by aFrontiers in immunology · 2018Article
- Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.Journal of immunology research · 2016Review
- Immune Evasion Strategies of Glioblastoma.Frontiers in surgery · 2016Review
- Loss of Phagocytic and Antigen Cross-Presenting Capacity in Aging Dendritic Cells Is Associated with Mitochondrial Dysfunction.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Restoration of defective cross-presentation in tumors by gemcitabine.Oncoimmunology · 2015Article
- Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that are critical for the generation of effective cytotoxic T lymphocyte (CTL) responses; however, their function and phenotype are often defective or altered in tumor-bearing hosts, which may limit their capacity to mount an effective tumor-specific CTL response. In particular, the manner in which exogenous tumor antigens are acquired, processed, and cross-presented to CD8 T cells by DCs in tumor-bearing hosts is not well understood, but may have a profound effect on antitumor immunity. In this paper, we have examined the role of DCs in the cross-presentation of tumor antigen in terms of their subset, function, migration, and location with the intention of examining the early processes that contribute to the development of an ineffective anti-tumor immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.